contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


real-heart-realheart-reaches-new-milestone-with-the-worlds-first-four-chamber-artificial-heart

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Scandinavian Real Heart operates in the medical technology sector. The company conducts research and development in observations of the physiology of the heart. The development of the company's product, a complete artificial heart, is taking place in collaboration with cardiac surgeons, researchers and engineers. The focus is on developing patented solutions that can imitate the blood circulation of the natural human heart, with the goal of being used by patients diagnosed with heart failure. The company was founded in 2007.

Scandinavian Real Heart

Press Release, 10 January 2023Scandinavian Real Heart AB, the company developing the world's first four-chamber total artificial heart (TAH), successfully extended the survival of animals implanted...

<div class="abstract">Press Release, 10 January 2023Scandinavian Real Heart AB, the company developing the world's first four-chamber total artificial heart (TAH), successfully extended the survival of animals implanted with Realheart's TAH.</div>Since the series of animal trials with the clinical version of the company's TAH began in 2022, Realheart has been able to increase survival time from one to four days.After implantation, the animal was able to stand up and eat. In addition, Scandinavian Real Heart was able to confirm key TAH performance criteria, including:<ul><li>No haemolysis (damage to red blood cells): Haemolysis due to mechanical stress caused by artificial hearts on blood cells is a major cause of severe side effects impacting survival of artificial heart patients over time.</li><li>No thromboembolic events (blood clots): Good blood flow and low mechanical stress in the TAH minimise the risk of very serious, and life-threatening consequences for patients, including stroke.&nbsp;</li><li>High pumping capacity and good right-left balance: The TAH can pump eight litres of blood per minute. This is significantly more capacity than what an adult human needs. The balance between blood flow from the right and left ventricles is crucial for survival.</li><li>Short procedure: A heart-lung machine used during the implantation of the TAH was disconnected after less than 2.5 hours. The extended use of a heart-lung machine during open heart surgeries poses considerable safety risks to patients. Realheart is developing its TAH to reduce time on a heart-lung machine and overall procedure times, therefore improving overall safety.</li></ul>''I am incredibly pleased with how much we have been able to achieve after just a few implantations of our TAH. The fact that we see no signs of haemolysis or blood clots, combined with the fact that we can achieve good left-right balance, a pulsatile blood flow, and natural blood pressure, is extremely satisfying. We are now moving forward with the aim of continuing to further prolong survival time by optimising the surgical methodology,'' said Ina Laura Perkins, CEO of Realheart. The company plans to initiate human clinical trials in 2024.This disclosure contains information that Real Heart is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information in this press release has been published through the agency of the contact persons set out below, at the time stated by Scandinavian Real Heart AB's news distributor Cision upon publication of this press release.

Real Heart: Realheart Reaches New Milestone With the World's First Four Chamber Artificial Heart